Recurrent Disease in Patients With Sporadic Pheochromocytoma and Paraganglioma
Authors' conclusion
Patients with sporadic PPGL require long-term follow-up, as supported by the 14.7% prevalence of recurrent disease, including recurrences at more than 10 years after first diagnosis. The nature of follow-up could be individualized according to tumor size, location, and biochemical phenotype.
Study context
- Population
- Patients with PPGL with genetic test results, multicenter
- Participants
- 1,127 patients
- Exposure
- Sporadic vs hereditary PPGL
- Outcome
- Prevalence of recurrence
Methodological detailsmulticenter
- Multicenter
Main finding
As reported in the abstract
P < 0.001
Observational data: associations, not effects.
Further findings
Timing of recurrence in sporadic recurrent PPGL
- Diagnosed ≥10 years after first diagnosis
- 29.1%
- Diagnosed ≥15 years after first diagnosis
- 17.7%
Independent predictors of recurrence in sporadic PPGL (multivariable regression)
- Noradrenergic/dopaminergic phenotype: HR
- 2.73 (95% CI 1.553-4.802; P < 0.001)
- Larger primary tumor size: HR
- 1.82 (95% CI 1.113-2.962; P = 0.017)
- Extra-adrenal location: HR
- 1.79 (95% CI 1.002-3.187; P = 0.049)
Original publication
Recurrent Disease in Patients With Sporadic Pheochromocytoma and Paraganglioma. J Clin Endocrinol Metab. Published 3 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →